MannKind (NASDAQ:MNKD) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

MannKind (NASDAQ:MNKD) had its price target raised by equities research analysts at Cantor Fitzgerald from $8.00 to $10.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald‘s price target suggests a potential upside of 165.96% from the company’s current price.

Other equities analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of MannKind in a research note on Friday, October 2nd. Zacks Research upgraded MannKind from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Chardan Capital started coverage on MannKind in a research report on Monday, October 19th. They issued a “buy” rating and a $10.00 price objective for the company. Wells Fargo & Company dropped their price objective on MannKind from $14.00 to $13.00 and set an “overweight” rating for the company in a report on Thursday, August 6th. Finally, HC Wainwright restated a “buy” rating on shares of MannKind in a research report on Thursday, July 23rd. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.31.

MannKind Price Performance

MNKD opened at $3.76 on Friday. The stock has a market capitalization of $1.21 billion, a P/E ratio of -28.92 and a beta of 1.10. The company’s 50 day simple moving average is $3.55 and its 200-day simple moving average is $3.72. MannKind has a one year low of $2.23 and a one year high of $6.51.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.05. The firm had revenue of $101.87 million during the quarter, compared to the consensus estimate of $107.74 million. The firm’s quarterly revenue was up 24.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.03 earnings per share. As a group, analysts anticipate that MannKind will post -0.21 EPS for the current year.

Insider Transactions at MannKind

In other MannKind news, Director Steven Binder sold 39,051 shares of the firm’s stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $3.29, for a total transaction of $128,477.79. Following the transaction, the director owned 713,258 shares in the company, valued at approximately $2,346,618.82. This trade represents a 5.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.60% of the company’s stock.

Institutional Trading of MannKind

A number of hedge funds have recently modified their holdings of the company. AdvisorNet Financial Inc acquired a new position in MannKind during the third quarter valued at approximately $39,000. Sterling Capital Management LLC increased its stake in MannKind by 864.1% in the third quarter. Sterling Capital Management LLC now owns 10,422 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 9,341 shares in the last quarter. Corient Private Wealth LP bought a new stake in MannKind in the second quarter valued at approximately $47,000. Allworth Financial LP raised its holdings in shares of MannKind by 2,013.4% during the second quarter. Allworth Financial LP now owns 11,074 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 10,550 shares during the period. Finally, Independent Financial Group LLC acquired a new stake in shares of MannKind during the first quarter worth $31,000. 49.55% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: MannKind said it expects about $1 billion in revenue from its United Therapeutics deal over 2027–2030 and is targeting profitability in the fourth quarter. Those milestones could support the longer-term outlook if achieved. Article: MannKind anticipates $1B in revenue from United Therapeutics deal
• Positive Sentiment: Third-quarter revenue rose 24% year over year, and one reported earnings comparison showed a smaller loss than analysts expected. Analysts’ consensus target price was reported at $8.08, suggesting favorable analyst expectations, though targets are not guarantees. Article: MannKind consensus target price
• Negative Sentiment: Quarterly revenue of $101.9 million fell short of the roughly $107.7 million consensus, while the company remained loss-making. The revenue miss and ongoing losses may be weighing on shares despite year-over-year growth and the forward-looking targets. Article: MannKind Reports Third Quarter 2026 Financial Results

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).